Skip to content

Biopharmaceutics Classification System Waiver Option in Product-Specific Guidances

    Back to: Advancing Generic Drug Development 2025

    Introduction

    Angelique Besold, PhD
    Senior Pharmacologist
    DBII | OB | OGD | CDER | FDA

    Presenter

    CDR Yi Zhang, PhD
    Senior Scientific Advisor
    DTPII | ORS | OGD | CDER | FDA

    Leave a Comment

    Your email address will not be published. Required fields are marked *